Anebulo Pharmaceuticals, Inc.

NasdaqCM ANEB

Anebulo Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2024

Anebulo Pharmaceuticals, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: ANEB

Anebulo Pharmaceuticals, Inc.

CEO	Mr. Richard Anthony Cunningham
IPO Date	May 7, 2021
Location	United States
Headquarters	1415 Ranch Road 620 South
Employees	2
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Key trends

Past 5 years